Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Reply to E. Paulino et al
Richard T Penson, Elizabeth S Lowe
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Reply to S. Gulia et al
Paul DiSilvestro, Elizabeth S Lowe, Ralph Bloomfield
The Journal of Clinical Endocrinology and Metabolism
|
April 10, 2008
The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome
Jakub Mieszczak, Elizabeth S Lowe, Paul Plourde, et al.
Cancer Chemotherapy and Pharmacology
|
October 18, 2011
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
Mitchell E Gross, Lawrence Leichman, Elizabeth S Lowe, et al.
Breast Cancer Research : BCR
|
September 26, 2013
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
Rebecca A Dent, Geoffrey J Lindeman, Mark Clemons, et al.
Breast Cancer Research and Treatment
|
January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
Irene Kuter, Julia M W Gee, Roberto Hegg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Jung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Head & Neck
|
October 30, 2014
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma
Vasiliki A Papadimitrakopoulou, Steven J Frank, Ezra W Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
Stan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2020
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Richard T Penson, Ricardo Villalobos Valencia, David Cibula, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Reply to E. Paulino et al
Richard T Penson, Elizabeth S Lowe
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Reply to S. Gulia et al
Paul DiSilvestro, Elizabeth S Lowe, Ralph Bloomfield
The Journal of Clinical Endocrinology and Metabolism
|
April 10, 2008
The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome
Jakub Mieszczak, Elizabeth S Lowe, Paul Plourde, et al.
Cancer Chemotherapy and Pharmacology
|
October 18, 2011
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
Mitchell E Gross, Lawrence Leichman, Elizabeth S Lowe, et al.
Breast Cancer Research : BCR
|
September 26, 2013
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
Rebecca A Dent, Geoffrey J Lindeman, Mark Clemons, et al.
Breast Cancer Research and Treatment
|
January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
Irene Kuter, Julia M W Gee, Roberto Hegg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Jung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Head & Neck
|
October 30, 2014
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma
Vasiliki A Papadimitrakopoulou, Steven J Frank, Ezra W Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
Stan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2020
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Richard T Penson, Ricardo Villalobos Valencia, David Cibula, et al.
Page
of 3